
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd presents a compelling outlook due to strong market preferences for its leading product, Brukinsa, which is projected to drive sustained long-term growth, with estimated peak sales reaching approximately $7.1 billion. The company's innovative sonrotoclax is seen as a leading BCL2 inhibitor, with expectations of surpassing competitors like venetoclax in efficacy and safety, potentially contributing to an additional $350 million in revenues. Furthermore, BeOne's strategic focus on physician outreach and competitive contracting is anticipated to bolster Brukinsa's growth trajectory, positioning the company for profitable operations and positive free cash flow by 2025, alongside strong year-over-year growth projections exceeding 40%.
Bears say
The outlook for BeOne Medicines Ltd appears negative due to several fundamental concerns. The company faces challenges such as slower-than-expected uptake of its current commercial products, potential failures in additional indications, and pipeline programs, which could significantly impact revenue generation. Additionally, risks related to geopolitical perceptions, high cash burn without guaranteed returns, and a competitive oncology market, particularly for its flagship product BRUKINSA, further complicate its financial prospects.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares